絞り込み

16532

広告

The Use of Denosumab in a Nonagenarian with Primary Hyperparathyroidism.

著者 Shalaby T , Anandappa S , Sivappriyan S , Kumar J
Eur Endocrinol.2014 Aug ; 10(2):151-152.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (21view , 0users)

Full Text Sources

Denosumab is a monoclonal antibody which is currently licensed in the UK drug market for the prevention of skeletal-related events secondary to malignancy (excluding myeloma). This monoclonal antibody is a 6 monthly subcutaneous injection that works by lowering calcium levels. When used in a 90 year old patient with primary hyperparathyroidism it demonstrated a dramatic reduction in the calcium level which had proven difficult to reduce by bisphosphonates and who was not a candidate for surgical intervention.
PMID: 29872480 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード